Login to Your Account



Pfizer Acquires Pain Drug Developer Icagen for $56M

By Catherine Shaffer


Thursday, July 21, 2011
Pfizer Inc. will acquire approximately 8.3 million shares in Icagen Inc. at a share price of $6 to become the majority shareholder in the company. Icagen is developing its pipeline of drugs targeted at ion channels for pain disorders, and three of its targets are covered by a 2007 collaboration agreement with Pfizer.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription